GURUFOCUS.COM » STOCK LIST » Oceania » Australia » ASX » Vectus Biosystems Ltd (ASX:VBS) » Definitions » Profitability Rank
Switch to:

Vectus Biosystems (ASX:VBS) Profitability Rank

: 0 (As of Dec. 2022)
View and export this data going back to 2016. Start your Free Trial

Vectus Biosystems has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Vectus Biosystems's Operating Margin % for the quarter that ended in Dec. 2022 was -27,866.67%. As of today, Vectus Biosystems's Piotroski F-Score is 2.


Competitive Comparison

For the Biotechnology subindustry, Vectus Biosystems's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Vectus Biosystems Profitability Rank Distribution

For the Biotechnology industry and Healthcare sector, Vectus Biosystems's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Vectus Biosystems's Profitability Rank falls in comparison to its industry or sector. The grey bar indicates the Profitability Rank's extreme value range as defined by GuruFocus.



Vectus Biosystems Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Vectus Biosystems has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Vectus Biosystems's Operating Margin % for the quarter that ended in Dec. 2022 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2022 ) / Revenue (Q: Dec. 2022 )
=-2.508 / 0.009
=-27,866.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Vectus Biosystems has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Vectus Biosystems Profitability Rank Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Vectus Biosystems (ASX:VBS) Business Description

Vectus Biosystems logo
Traded in Other Exchanges
N/A
Address
3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems (ASX:VBS) Headlines

No Headlines